Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT07183488
Recruiting Not applicable

Metabolic Effects of Short-Chain Fatty Acids in Healthy Individuals

NCT07183488 · tracked via the Priya Life Science Denmark tracker
Sponsor
University of Copenhagen
Phase
Not applicable
Started
2025-09-10
Last updated
2026-03-10

Condition(s) studied

HealhtyOther: Short-Chain Fatty Acid (SCFA)Other: Butyrate (C4)Other: Propionate (C3)

Investigational drug(s) / intervention(s)

Propionate followed by ButyrateButyrate followed by PropionatePropionate followed by ButyrateButyrate followed by Propionate

Propionate followed by Butyrate: The participants will consume Short-chain fatty acid propionate (SCFA-PRO) followed by Short-Chain Fatty Acid Butyrate (SCFA-BUT).

Butyrate followed by Propionate: • The participants will consume Short-chain fatty acid Butyrate (SCFA-BUT) followed by Short-Chain Fatty Acid Propionate (SCFA-PRO).

Propionate followed by Butyrate: • The participants will consume Short-Chain Fatty Acid propionate (SCFA-PRO) followed by Short-Chain Fatty Acid Butyrate (SCFA-BUT).

Butyrate followed by Propionate: The participants will consume Short-Chain Fatty Acid Butyrate (SCFA-BUT) followed by Short-Chain Fatty Acid Propionate (SCFA-PRO).

Study summary

The primary objective of this study is to investigate the acute physiological and metabolic effects of ingesting the short-chain fatty acids (SCFA)s propionate (three carbon atoms long; C3:0) and butyrate (C4:0) in healthy men and women. This aim will be addressed through a block-randomized cross-over study including two visits with acute intake of propionate and butyrate, respectively.

The hypothesis is that plasma ketone body levels will increase during the first three hours after intake of butyrate, but not propionate, in healthy individuals in the overnight fasted state.

Eligibility

Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Male or female. * Age between 18-40 years old * BMI between 18.5-29 Exclusion Criteria: * Diabetes * Kidney- or liver disease * Pregnant, lactating or planning to become pregnant within the study period * Supplementation with SCFAs * Supplementation with B12 vitamin * Special dietary habits (e.g. vegan/ketogenic diet) * Ongoing cancer treatment * Metabolic or absorptive disorders, gastric bypass operation, or use of medication affecting metabolism or food absorption * Crohn's disease, ulcerative colitis or short bowel syndrome * Inability, physically or mentally, to comply with the procedure required by the study protocol as evaluated by the primary investigator, study manager or clinical responsible

Primary outcome measure(s)

  • Ketone Bodies — On day 1 (test day 1) and day 2 (test day 2) at baseline (-30 min and 0 min) and post intake (10 min, 15 min, 22.5 min, 30 min, 45 min, 60 min, 90 min, 120 min, and 180 min).
    To measure the effect of Short-Chain Fatty Acid Butyrate (SCFA-BUT) and Short-Chain Fatty Acid Propionate (SCFA-PRO) on circulating ketone body concentrations.

Trial sites (1)

FacilityCityRegionStatus
University of Copenhagen Copenhagen Copenhagen N Recruiting

More University of Copenhagen trials in Denmark

Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms Recruiting
Ayurvedic Diet in Myxedema Recruiting
Does Paracetamol Influence the Release of Gut Hormones, Glucose Absorption and Glycemia? Recruiting
GastroFlow: Investigation of the Gastrointestinal Blood Flow in Patients With Postprandial Hypotension Enrolling by invitation
The Effect of Fasting on Peak Fat Oxidation, Mitochondrial Coupling and Extracellular Matrix Recruiting

Other trials for the same condition

Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07183488 on ClinicalTrials.gov ↗ ← All trials in Denmark